A Phase 1, Multicenter, Open-Label, First-in-Human, Dose-Escalation Study of the Oral Hedgehog Inhibitor Sonidegib (LDE225) in Patients With Advanced Solid Tumors by Rodon, Jordi et al.
Zurich Open Repository and
Archive
University of Zurich
Main Library
Strickhofstrasse 39
CH-8057 Zurich
www.zora.uzh.ch
Year: 2014
A Phase 1, Multicenter, Open-Label, First-in-Human, Dose-Escalation Study
of the Oral Hedgehog Inhibitor Sonidegib (LDE225) in Patients With
Advanced Solid Tumors
Rodon, Jordi; Tawbi, Hussein A; Thomas, Anne L; Stoller, Ronald; Turtschi, Christian P; Baselga, Jose;
Sarantopoulos, John; Mahalingam, Devalingam; Shou, Yaping; Moles, Melissa A; Yang, Lin; Granvil,
Camille; Hurh, Eunju; Rose, Kristine L; Amakye, Dereck D; Dummer, Reinhard; Mita, Alain C
Abstract: PURPOSE: This phase 1 trial was undertaken to determine the maximum tolerated dose
(MTD), dose-limiting toxicities (DLTs), safety, tolerability, pharmacokinetics (PK), pharmacodynamics,
and preliminary antitumor activity of the novel smoothened inhibitor sonidegib (LDE225), a potent in-
hibitor of hedgehog (Hh) signaling, in patients with advanced solid tumors. EXPERIMENTAL DESIGN:
Oral sonidegib was administered to 103 patients with advanced solid tumors, including medulloblastoma
(MB) and basal cell carcinoma (BCC), at doses ranging from 100 to 3000 mg daily and 250 to 750 mg twice
daily, continuously, with a single-dose PK run-in period. Dose-escalations were guided by a Bayesian
logistic regression model. Safety, tolerability, efficacy, PK, and biomarkers in skin and tumor biopsies
were assessed. RESULTS: The MTDs of sonidegib were 800 mg daily and 250 mg twice daily. The main
DLT of reversible grade 3/4 elevated serum creatine kinase (18% of patients) was observed at doses ￿
the MTD in an exposure-dependent manner. Common grade 1/2 adverse events included muscle spasm,
myalgia, gastrointestinal toxicities, increased liver enzymes, fatigue, dysgeusia, and alopecia. Sonidegib
exposure increased dose proportionally up to 400 mg daily, and displayed nonlinear PK at higher doses.
Sonidegib exhibited exposure-dependent reduction in GLI1 mRNA expression. Tumor responses observed
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Statement of Translational Relevance 
Aberrant hedgehog (Hh) pathway activity has been linked to the pathogenesis of many 
cancers. The results of this phase 1 trial further advance the emerging clinical experience of 
Hh pathway inhibitors in patients with cancer. Oral sonidegib (LDE225) blocks the Hh pathway 
by selective inhibition of smoothened. Sonidegib exhibits an acceptable safety profile, 
exposure-dependent target inhibition, and clinically relevant antitumor effect in patients with 
locally advanced or metastatic basal cell carcinoma (BCC) and relapsed medulloblastoma 
(MB). The toxicities identified are manageable and reversible upon discontinuation of 
treatment. Furthermore, a five-gene Hh signature assay demonstrated a strong association 
between tumor responses and Hh pathway activation, thus supporting its use as a patient 
selection tool in future studies. These data support ongoing clinical investigations of sonidegib 
as a single agent in BCC and Hh pathway-activated MB, and as a combination partner with 
other agents in other malignant disease settings.  
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ABSTRACT 
 
Purpose 
This phase 1 trial was undertaken to determine the maximum tolerated dose (MTD), dose-
limiting toxicities (DLTs), safety, tolerability, pharmacokinetics (PK), pharmacodynamics, and 
preliminary antitumor activity of the novel smoothened inhibitor sonidegib (LDE225), a potent 
inhibitor of hedgehog (Hh) signaling, in patients with advanced solid tumors.  
Experimental Design 
Oral sonidegib was administered to 103 patients with advanced solid tumors, including 
medulloblastoma (MB) and basal cell carcinoma (BCC), at doses ranging from 100 to 3000 mg 
daily and 250 to 750 mg twice daily, continuously, with a single-dose PK run-in period. Dose-
escalations were guided by a Bayesian logistic regression model. Safety, tolerability, efficacy, 
PK, and biomarkers in skin and tumor biopsies were assessed.  
Results 
The MTDs of sonidegib were 800 mg daily and 250 mg twice daily. The main DLT of reversible 
grade 3/4 elevated serum creatine kinase (18% of patients) was observed at doses ≥ the MTD 
in an exposure-dependent manner. Common grade 1/2 adverse events included muscle 
spasm, myalgia, gastrointestinal toxicities, increased liver enzymes, fatigue, dysgeusia, and 
alopecia. Sonidegib exposure increased dose proportionally up to 400 mg daily, and displayed 
nonlinear PK at higher doses. Sonidegib exhibited exposure-dependent reduction in GLI1 
mRNA expression. Tumor responses observed in patients with MB and BCC were associated 
with evidence of Hh pathway activation. 
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Conclusions 
Sonidegib has an acceptable safety profile in patients with advanced solid tumors and exhibits 
antitumor activity in advanced BCC and relapsed MB, which is strongly associated with 
activated Hh pathway, as determined by gene expression. 
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INTRODUCTION 
The hedgehog (Hh) signaling pathway plays a key role during embryo-fetal development of the 
brain, bones, and muscles (1). During the postnatal period and adulthood, Hh pathway activity 
is involved in the regulation of bone development, tissue maintenance and repair, and 
maintenance of stem cell populations (hair follicles) (1, 2). Aberrant Hh pathway activation has 
been linked with the pathogenesis of many human cancers through Hh ligand-dependent and 
ligand-independent mechanisms. 
Genetic alterations including loss-of-function mutations in the negative regulators Patched 1 
(PTCH1) and/or Suppressor of Fused, or less frequently gain-of-function mutations in the 
positive regulator Smoothened (SMO), lead to ligand-independent pathway activation and 
have been linked to basal cell carcinoma (BCC), medulloblastoma (MB), and 
rhabdomyosarcoma (2). Overexpression of Hh ligand has been observed in pancreatic, 
colorectal, lung, breast, prostate, esophageal, and gastric tumors (2). Therefore, the Hh 
pathway has become an attractive therapeutic target. Inhibitors targeting SMO, including 
vismodegib, which is approved by the US Food and Drug Administration (FDA) for the 
treatment of metastatic or locally advanced BCC, are currently being investigated in clinical 
trials (3-9).  
Sonidegib (LDE225), N-(6-((2S,6R)-2,6-dimethylmorpholino)pyridin-3-yl)-2-methyl-40-
(trifluoromethoxy)biphenyl-3-carboxamide, a novel selective inhibitor of SMO, was identified in 
a cell-based high-throughput screen (Supplementary Fig. S1) (10). Sonidegib demonstrated 
high tissue penetration (including blood-brain barrier) and good oral bioavailability in preclinical 
studies (10). Oral administration of sonidegib in mouse MB models Ptch+/− p53−/− and Ptch+/− 
Hic1+/− (hypermethylated in cancer 1) resulted in complete suppression of glioma-associated 
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oncogene homolog 1 (GLI1) and tumor regression, suggesting targeted inhibition of Hh 
signaling (11). 
We report results from a first-in-human, dose-escalation, phase 1 study with sonidegib in adult 
patients with advanced solid tumors. The study population was enriched with patients with 
locally advanced or metastatic BCC and relapsed MB. This study established the maximum 
tolerated dose (MTD) and dose-limiting toxicity (DLT) of continuous daily oral sonidegib 
administration. Additionally, safety, pharmacokinetics (PK), pharmacodynamics (PD), and 
preliminary antitumor activity were assessed. 
PATIENTS AND METHODS 
Patient Population 
Adult patients with histologically or cytologically confirmed advanced solid tumors, including 
MB, whose  disease  progressed despite standard therapy or for whom no standard therapy 
was available were eligible. Other key inclusion criteria were measurable or evaluable disease 
defined by Response Evaluation Criteria In Solid Tumors (RECIST 1.0) (12) or the Neuro-
Oncology Criteria for Tumor Response (MB only) (13, 14) and Eastern Cooperative Oncology 
Group (ECOG) performance status ≤ 2. In addition, all patients must have had adequate bone 
marrow (absolute neutrophil count ≥ 1.5 × 109/L, hemoglobin ≥ 9 g/dL, and platelets ≥ 100 × 
109/L), liver (serum total bilirubin ≤ 1.5 × upper limit of normal [ULN] and aspartate 
aminotransferase and alanine aminotransferase ≤ 2.5 × ULN or ≤ 5.0 × ULN if liver metastases 
are present), and kidney function (serum creatine ≤ 1.5 × ULN or 24-hour creatinine clearance 
of ≥ 50 mL/min). Patients were excluded if they had a history of a brain tumor or brain 
metastases (except relapsed MB), clinically significant cardiac disease, or gastrointestinal 
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dysfunction that might impair sonidegib absorption. Treatment with strong inhibitors or inducers 
of cytochrome P450 (CYP) 3A4/5 or drugs metabolized by CYP2B6 or CYP2C9, which have a 
narrow therapeutic index, was prohibited during the study. 
All patients provided written informed consent before enrollment. The study followed the ethical 
principles of the Declaration of Helsinki, the International Conference on Harmonisation 
Guideline for Good Clinical Practice, and local regulations (European Directive 2001/20/EC 
and US Code of Federal Regulations Title 21). The protocol and amendments were approved 
by the institutional review board, independent ethics committee, or research ethics board at 
each center.  
Study Design 
The primary objective of this dose escalation, multicenter, open-label phase 1 study was to 
determine the MTD and DLTs of oral sonidegib, administered on a continuous daily schedule. 
Additional objectives included safety, PK, PD, and antitumor activity. During dose escalation, 
all patients received a single oral dose of sonidegib in a 7-day PK run-in period to characterize 
the PK profile of sonidegib. Once the MTD was determined for the once-daily regimen, 
additional patients were enrolled to ensure a minimum of 22 patients were treated at the MTD 
to provide a 90% probability of detecting adverse events (AEs) with an incidence of 10% and 
permit further assessment of PK, PD effects, and antitumor activity. Twice-daily dosing was 
also tested to explore the effect of dose fractionation and MTD. 
Sequential cohorts of patients were treated with escalating doses of sonidegib once (100, 200, 
400, 800, 1000, 1500, or 3000 mg) or twice daily (250, 400, or 750 mg), continuously in a 28-
day cycle. Twice-daily dosing was evaluated to address apparent solubility-limited absorption 
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at doses > 400 mg once daily. A minimum of three evaluable patients were required to make 
dose-escalation decisions after completing cycle 1. Additional patients were enrolled to allow 
for dropouts and to better define the safety, PK, or PD of sonidegib at a given dose. Enrollment 
of patients with MB and advanced BCC was allowed at previously well-tolerated doses during 
the dose-escalation phase. 
A two-parameter Bayesian logistic regression model for escalation with overdose control was 
used to guide dose escalation decisions (15, 16). A DLT was defined as a significant AE or 
abnormal laboratory parameter adjudged to be Common Terminology Criteria for Adverse 
Events (CTCAE version 3.0) grade ≥ 3 in severity and considered unrelated to disease 
progression, intercurrent illness, or concomitant medications. The MTD was defined as the 
highest dose of sonidegib predicted to have < 25% probability of a DLT rate of ≥ 33% during 
cycle 1 (first 28 days). After tolerating the assigned dose for at least two cycles, intrapatient 
dose escalations were permitted. Dose-escalation decisions were impacted by the emergence 
of late-onset, reversible grade 3/4 elevated serum creatine kinase (CK), occurring primarily 
during cycle 2. 
Safety Evaluations 
Safety was assessed according to CTCAE version 3.0 guidelines (17). Assessments included 
regular laboratory evaluations, physical examinations, vital signs, weight, and periodic 
electrocardiogram recordings. All patients were monitored for safety from the first dose until 
28 days after the final dose. Additional monitoring, including weekly serum CK during cycle 2 
and on the first day of subsequent cycles, was implemented.  
PK Assessments and Analyses 
Research. 
on February 17, 2014. © 2014 American Association for Cancerclincancerres.aacrjournals.org Downloaded from 
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. 
Author Manuscript Published OnlineFirst on February 12, 2014; DOI: 10.1158/1078-0432.CCR-13-1710 
10 
 
Blood Sample Collection and Handling—Blood samples for pharmacokinetic (PK) analyses 
were collected throughout the study. For the PK run-in period, serial blood samples were 
collected starting on day 1 (ending on day 5) at predose and 0.5, 1, 2, 4, 6, 8, 24, 48, 72, and 
96 hours postdose. Serial blood samples were also collected on day 15 of cycle 1 at predose 
and 0.5, 1, 2, 4, 6, and 8 hours postdose. Blood samples were also collected predose on days 
1, 8, 16, and 22 of cycle 1; days 1, 2, 8, 15, 16, and 22 of cycle 2; and day 1 of all subsequent 
cycles. Samples were processed and frozen at ≤ 70°C within 90 minutes of the collection. 
Preparation and Analysis of Plasma Samples—Plasma samples were prepared using a 
protein precipitation extraction procedure, and sonidegib concentrations were determined 
using a validated liquid chromatography (LC)/mass spectrometry (MS)/MS assay using an API 
5000™ triple quadrupole mass spectrometer from AB Sciex (Foster City, CA, USA) equipped 
with an electrospray interface. Sample extracts were analyzed using gradient reverse-phase 
chromatography with a Capcell Pak C18 ACR, 150 × 4.6 mm ID, 5-μm particles (Shiseido Co 
Ltd, Tokyo, Japan). The mobile phase consisting of water/0.1% ammoniac solution followed by 
acetonitrile/isopropanol (8:2 vol/vol) was pumped through the column at a flow rate of 1.0 
mL/min. Positive-ion multiple reaction monitoring (MRM) with a labeled internal control and a 
lower limit of quantitation of 0.0247 ng/mL (using 0.050 mL of plasma) was used for detection. 
The MRM transition monitored for sonidegib, and the labeled internal standard was m/z 486.07 
to 428.08 and 490.07 to 432.08, respectively. The LC/MS/MS chromatograms of all analyzed 
baseline samples showed no interfering peaks, demonstrating selectivity of the method. 
Intraday and interday precision as represented by the coefficient of variation and accuracy as 
represented by the mean bias were within 20%. The validated method is suitable for the 
determination of sonidegib in human plasma.  
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PK Assessments—PK parameters were calculated using noncompartmental methods with 
WinNonlin®, version 5.2 (Pharsight, Mountain View, CA, USA). Peak plasma concentration 
(Cmax) and time to reach Cmax (Tmax) were obtained from individual sonidegib concentration-time 
profiles. Area under the plasma concentration-time curve (AUC) values were calculated using 
the linear trapezoidal rule. Steady state was defined as a stable plasma trough concentration 
in at least two consecutive samples. Accumulation ratios were calculated by dividing the 
average plasma trough concentration at steady state by the trough concentration after the first 
dose. 
Biomarker and Antitumor Evaluations 
Fresh or archival tumor samples were collected when available, and biopsies of normal skin 
were collected from all patients before sonidegib treatment, at the end of cycles 1 and 2, and 
within 14 days after the last dose. RNA was extracted from tissue samples and analyzed by 
reverse transcriptase–polymerase chain reaction (RT-PCR) to measure GLI1 expression and 
Hh pathway activation status, based on the five-gene Hh signature assay (18, 19). 
All potential sites of tumor lesions were evaluated by computed tomography, magnetic 
resonance imaging, or physical examination (locally advanced BCCs) at baseline and every 
8 weeks. Antitumor activity was determined according to RECIST 1.0 (12) and the Neuro-
Oncology Criteria of Tumor Response (MB only) (13, 14). [18F]-fluorodeoxyglucose positron 
emission tomography (FDG-PET) was performed in a subset of patients at baseline, day 28 of 
cycles 1 and 2, and post treatment to supplement RECIST assessments. Percent changes 
from baseline standardized uptake value (SUV) using the average over lesions per patient 
were determined for patients with at least one lesion ≥ 2 cm with a tumor-to-background ratio 
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of ≥ 2. Metabolic partial response (PR) was defined as a decrease of ≥ 25% in summed 
maximum SUV in the target lesion as per the recommendations proposed by Weber et al (20). 
Statistical Analyses 
Demographics, safety, efficacy, and relevant PK and pharmacodynamic measurements were 
summarized using descriptive statistics and contingency tables. Study data included all patient 
data from the dose-escalation and enrichment cohorts until all patients had completed at least 
three cycles of treatment or discontinued the study. 
RESULTS 
Patient Demographics and Clinical Characteristics 
A total of 103 patients, comprising 73 and 30 patients on the once-daily and twice-daily 
schedules, respectively, were enrolled between March 2009 and June 2011. Overall, 16 
patients with BCC and nine patients with MB were treated. Primary tumor site, previous 
antineoplastic therapies, and ECOG performance status of patients enrolled are listed in Table 
1.  
Safety Findings 
Sonidegib was generally well tolerated with typically mild (grade 1/2)  AEs (Table 2). Patients 
comprising the dose-decision sets are listed in Supplementary Table S1. Most common 
treatment-related grade 1/2 AEs experienced by > 10% of patients included nausea, 
dysgeusia, anorexia, vomiting, muscle spasms, myalgia, increased serum CK, 
fatigue/asthenia, and alopecia, characterized by gradual thinning of the hair. Notable grade 3/4 
AEs occurring in < 5% of all treated patients included weight loss, myalgia, hyperbilirubinemia, 
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dizziness, and asthenia. There were no deaths due to drug-related toxicities. Dose reduction 
occurred in 17 patients (17%), mostly treated at doses > 800 mg. Twenty patients (19%) 
permanently discontinued treatment because of AEs, mostly associated with CK elevation (14 
of 20). Reversible grade 3/4 serum CK elevation was considered to be dose limiting in 19 
patients (18%) at doses ≥ 800 mg once daily and ≥ 250 mg twice daily (Supplementary Table 
S1). These DLTs tended to occur 3 to 6 weeks after treatment initiation in an exposure-
dependent manner (Fig. 1). Due to the delayed onset, reports of DLTs initially appeared to be 
limited to high-dose cohorts; however, after further evaluation in expanded cohorts, two of 26 
patients and two of 14 patients experienced DLTs at 800 mg once daily and 250 mg twice 
daily, respectively. Thus, these doses fulfilled the prespecified criteria for MTD. In most cases, 
elevated CK was associated with myalgia. However, some patients reported myalgia and 
muscle spasm without CK elevation. Treatment-emergent CK elevation resolved within 4 to 8 
weeks of drug discontinuation. No concurrent renal dysfunction was observed in any patient. 
Of the patients with CK elevation, eight resumed treatment on a reduced dose without 
recurrence. Eight of 19 patients with DLTs also experienced grade 3/4 AEs including increased 
aspartate aminotransferase, alanine aminotransferase, or myoglobin; muscular weakness; and 
myositis. No clinically significant changes in CK-MB suggestive of cardiac muscle injury were 
noted. In three cases, the DLTs were reported as rhabdomyolysis, primarily based on elevated 
blood CK ± myoglobin levels without evidence of renal dysfunction. CK elevation in these 
patients resolved following discontinuation of sonidegib. No additional therapy was required in 
one patient—the other two patients received sodium chloride (n = 1) or furosemide (n = 1). 
Treatment with sondiegib was not resumed in these patients. 
Pharmacokinetics 
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PK parameters were calculated for 102 patients based on the single-dose PK run-in and for 82 
patients on day 15 of daily dosing. Mean sonidegib plasma concentration-time profiles 
following the PK run-in period prior to initiating continuous dosing are presented 
(Supplementary Fig. S2). Relevant PK parameters derived from the plasma concentration-time 
curves on PK run-in and day 15 of cycle 1 are summarized in Table 3. Sonidegib was 
absorbed after oral administration, with a median Tmax of 2 hours (range 1–48 hours) for all 
dosing regimens and doses combined. Sonidegib plasma exposure (Cmax and AUC) after 
single-dose administration increased dose proportionally from 100 to 400 mg and less than 
dose proportionally above 400 mg. After repeated once-daily dosing from 100 to 3000 mg, 
Cmax and AUC on cycle 1, day 15 increased approximately dose proportionally up to 400 mg 
and less than dose proportionally above 400 mg. After twice-daily dosing from 250 to 750 mg, 
Cmax and AUC on cycle 1, day 15 increased less than dose proportionally. Twice-daily dosing 
resulted in higher systemic exposures compared with the equivalent once-daily regimen. The 
7-day PK run-in phase implemented in this study was not long enough to allow for accurate 
estimation of the terminal half-life (t1/2), oral apparent clearance, or volume of distribution using 
noncompartmental methods. Based on the trough plasma concentration over time in patients 
monitored for a sufficiently long period without dose changes, steady state seemed variable 
and was achieved after 2 to 24 weeks of repeated dosing, with a median accumulation of 16-
fold across the dose groups based on Cmin. The estimated median effective elimination t1/2 of 
sonidegib, calculated on the basis of the accumulation ratio, was ≈ 11 days. The interpatient 
coefficients of variation (CVs) for day 15 Cmax and AUC were 39% to 113% and 33% to 122%, 
respectively, across the dose range of 100 to 3000 mg/day for all dosing regimens. At the MTD 
of 800 mg once daily and 250 mg twice daily, the day 15 exposures were similar, with CVs for 
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Cmax of 54% and 44% and AUC of 50% and 33%, respectively. The median accumulation ratio 
in 11 patients treated at 800 mg once daily was 16-fold. Increasing sonidegib dose and 
exposure were associated with increased odds of grade 3/4 CK elevation (Fig. 1, 
Supplementary Fig. S3).  
Target Inhibition 
Sonidegib treatment caused a reduction in GLI1 mRNA expression in tumor and skin (Fig. 2). 
Target inhibition in the tumor, as measured by GLI1 expression, was more pronounced than in 
the skin when both tissues were available for analyses (Supplementary Fig. S4). In general, 
the degree of target inhibition increased in a dose- and exposure-dependent manner, 
consistent with the utility of GLI1 expression as a pharmacodynamic marker for Hh pathway 
activation. However, in the limited number of samples analyzed, the reduction in GLI1 
expression did not correlate with tumor response (data not shown). 
Antitumor Activity 
Ninety-nine patients (96%) were evaluable for tumor response. Partial tumor responses were 
observed over the dose range of 100 to 1500 mg. Six of 16 patients with BCC (37.5%) and 
three of nine patients with MB (33%) achieved objective tumor responses (partial or complete 
response) according to RECIST and FDG-PET (Supplementary Table S2). In the 3 patients 
with MB with a PR, who were treated at 200, 800, and 1500 mg once daily, duration of 
response ranged from 4 to 8 months. One patient with MB, aged 25 years, with largely 
metastatic bone disease, did not have RECIST-measurable lesions; hence FDG-PET was 
used to monitor treatment effect. The metabolic PR in this patient, maintained for 8 months, 
was associated with symptomatic improvement (reduction in bone pain). A patient with locally 
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infiltrating BCC achieved a histologic complete response confirmed by multiple biopsies of the 
tumor and surrounding tissue after treatment at 400 mg twice daily (Fig. 3A). PRs were also 
observed in five patients with locally advanced or metastatic BCC (spread to the lungs), 
treated at 100, 800, or 1000 mg once daily and 250 mg twice daily (Fig. 3B and 3C). 
Interestingly, the tumor burden of the patient who achieved a PR at 250 mg twice daily 
continued to improve for several months after treatment discontinuation. In patients with BCC 
and MB, there was a strong association between tumor response and Hh pathway activation, 
as determined by a five-gene Hh signature RT-PCR assay (Supplementary Table S2) (18). 
Best overall response of stable disease (SD) was observed in 24 patients (23%), with duration 
of SD > 6 months in three patients with lung adenocarcinoma, spindle cell sarcoma, and BCC. 
DISCUSSION 
Continuous daily oral administration of sonidegib exhibited an acceptable safety profile, 
exposure-dependent target inhibition, and antitumor activity. The vast majority of AEs were 
mild to moderate in severity. Treatment-related AEs were manageable and reversible after 
discontinuation of drug. The majority of treatment-related AEs in this study have been similarly 
observed with other SMO inhibitors in phase 1 studies in patients with advanced solid tumors 
(3, 8). The toxicity profiles of these agents cannot be directly compared in the absence of 
head-to-head trials; however, the most commonly reported AEs in >10% across the agents 
include muscle spasms, dysgeusia, fatigue, and alopecia  (3, 8). 
Current understanding of the role for Hh signaling suggests that the observed slowly evolving 
diffuse alopecia, dysgeusia, and muscle-related events are likely mechanistic on-target 
toxicities (21-23). SMO inhibitors have been shown to induce muscle contraction and muscle 
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fiber twitching in primary human muscle cells, which is thought to be due effects on calcium 
influx, thus providing a potential mechanism for the muscle spasms observed in patients 
treated with sonidegib in this study (23). Reversible dose-limiting CK elevation of skeletal 
muscle origin (based on total CK/CK-MB ratio) occurred in 18% of patients across all doses (< 
10% at the MTD, 800 mg once daily), with no evidence of cardiac muscle injury. Overall, 
hyperCKemia (without evidence of renal impairment) was reported in ≈ 46% of patients with 
normal CK at baseline. Six patients with CK elevation also had grade 3/4 increases in serum 
transaminases without significant changes in other liver function tests, thus suggesting skeletal 
muscle origin. High drug exposure was associated with increased odds of grade 3/4 CK 
elevations (Fig. 1, Supplementary Fig. S3). Although resolution of CK levels was slower than 
expected for the known half-life of CK, it was not entirely consistent with the long half-life of 
sonidegib. Some patients had resolution of CK despite maintaining high drug concentrations. 
Additionally, recurrence was not observed on retreatment at a reduced dose. For the three 
patients with DLTs documented as rhabdomyolysis, CK elevation resolved following 
discontinuation of treatment with supportive care (sodium chloride or furosemide in two of the 
three patients). Furosemide was administered as a precaution, apparently to boost urinary 
output in one patient, though there was no evidence of impaired renal function. Not 
surprisingly, there was no clear relationship between the incidence of muscle cramps/spasms 
and hyperCKemia, as many patients experience muscle cramps/spasms without CK elevation 
following SMO inhibitor treatments (3, 8). Other drugs with potential to cause toxic myopathy 
should be used in caution with SMO inhibitors (24). 
The underlying reason for the relatively long half-life of sonidegib is unknown, although tight 
tissue and/or plasma protein binding can be speculated. High affinity protein binding was also 
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shown to contribute to the long half-life (> 7 days) of the SMO inhibitor vismodegib—a 
methanesulfonyl benzamide identified in a high-throughput screen (25). Sonidegib does not 
exhibit a time-dependent PK profile. The drug accumulation pattern over time and extent of 
accumulation at steady state are consistent with in vitro data showing lack of induction or time-
dependent inhibition of CYP enzymes (10). Sonidegib displayed nonlinear pharmacokinetics at 
higher doses, likely due to solubility-limited absorption, and not due to dose-dependent 
metabolism as shown by parallel decline of the plasma concentration profile across the dose 
range. Solubility-limited absorption also contributed to the nonlinear pharmacokinetics 
observed for vismodegib, however, slow metabolic elimination was also a factor (25). Although 
twice-daily dosing provided a higher systemic exposure than equivalent once-daily doses, it did 
not not appear to offer a clinically meaningful advantage over the once-daily regimen in this 
study. Therefore, the once-daily dosing regimen is currently recommended for further studies 
with sonidegib. However, the twice-daily dosing regimen may be considered in situations 
where a faster time to steady-state systemic concentration is desirable. 
This proof-of-concept study demonstrated that sonidegib induced target inhibition and 
antitumor activity at well-tolerated drug exposures in patients with BCC and MB, tumor types 
known to harbor activating mutations (2). Sonidegib exhibited dose- and exposure-dependent 
inhibition of GLI1 in tumor and normal skin biopsies. GLI1 inhibition at maximum drug 
exposure at steady state is expected to be higher than that observed at the end of cycle 1. 
Although GLI1 inhibition in other tumors was comparable to BCC (Supplementary Fig. S4), no 
objective responses were reported in these tumors. Similarly, GLI1 stromal expression in a 
patient with rectal cancer treated with saridegib in a phase 1 study was reduced (8); however, 
this patient did not respond to treatment. The lack of response in these patients is most 
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probably due to differences in the tumor dependency on Hh signaling (ie, ligand-dependent 
versus ligand-independent). In the case of ligand-dependent tumors, other factors and 
signaling pathways may be involved in tumorigenesis—therefore, inhibition of  Hh signaling 
alone may not be enough to induce a response. In phase 1 studies, both saridegib and 
vismodegib caused a reduction in GLI1 levels in approximately 74% of normal skin biopsies 
analyzed (3, 8). Taken together, these data suggest that GLI1 is an ideal marker for SMO 
inhibitor therapy, but not a marker for tumor response. Molecular alterations in other Hh 
pathway components in the patients who responded are unknown as mutational analyses were 
not conducted in this study; however, Hh pathway activity was assessed using the five-gene 
Hh signature assay, an RT-PCR-based assay, in fresh-frozen paraffin-embedded tumor 
samples—a strong association between tumor response and activated Hh pathway  was 
observed in patients with BCC and MB (18, 19).  
Similar responses in patients with advanced BCC (29-58%) have been observed in other 
phase 1 and 2 studies of SMO inhibitors (3, 4). The wide range of responses in these studies 
may be due in part to differences in patient populations and the methods of tumor evaluation 
across studies. In particular, assessment of response in BCC is confounded by the presence 
of residual scarring or fibrosis, making the standard provisions of RECIST sub-optimal. 
To date, responses in MB have been reported only for sonidegib and vismodegib (3, 18, 26-
29). Importantly, all responses occurred in patients with Hh-activated MB (18, 26-29). 
Complete and partial responses have been observed in patients with MB in our study and in a 
phase 1/2 study of sonidegib in children with tumors thought to be dependent on Hh signaling 
(phase 1) and children and adults with Hh-activated MB (18). A dramatic but transient 
regression of systemic metastatic disease (primarily in the bone) was observed in an adult 
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patient treated with vismodegib in the first-in-man phase 1 study and three of 20 adult patients 
achieved sustained responses in a phase 2 study in recurrent MB (3, 27, 28). Antitumor activity 
was also observed in one pediatric patient with Hh-activated MB treated with vismodegib in a 
phase 1 study (29).  
In conclusion, sonidegib treatment at the MTD of 800 mg daily and 250 mg twice daily was well 
tolerated and demonstrated dose- and exposure-dependent target inhibition. The antitumor 
activity in BCC and MB and mechanism-based toxicities observed demonstrate that sonidegib 
effectively inhibits Hh signaling. These results support the ongoing development of single-
agent sonidegib for treatment of advanced BCC and relapsed MB, and further exploration in 
combination therapies in other cancers (30-33). 
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TABLES 
Table 1. Demographic Summary and Disease Characteristics at Baseline  
Baseline Characteristics 
All Patients 
(n = 103) 
Age, median years (range) 59.0 (22–87) 
Male sex, % 61.2 
Primary site of cancer, n (%) 
Pancreas 19 (18.4) 
Colorectal 18 (17.5) 
Other GI tumors
a
 8 (7.8) 
BCC 16 (15.5) 
Lung 10 (9.7) 
Medulloblastoma 9 (8.7) 
Genitourinary tumorsb 5 (4.9) 
Breast 3 (2.9) 
Cutaneous melanoma 3 (2.9) 
Otherc 12 (11.7) 
Prior antineoplastic therapies, n (%)  
Surgery 91 (88.3) 
Radiotherapy 47 (45.6) 
Systemic therapyd 96 (93.2) 
Prior systemic therapiesd  
        1 20 (19.4) 
        2                                      22 (21.4) 
        > 2 54 (52.4) 
ECOG performance status, n (%)  
0 41 (39.8) 
1 55 (53.4) 
2 7 (6.8) 
Abbreviations: BCC, basal cell carcinoma; ECOG, Eastern Cooperative Oncology Group; GI, 
gastrointestinal. 
a Other GI tumors included cholangiocarcinoma (4), stomach (1), gall bladder (1), esophageal 
(1), and small intestine (1). 
b Genitourinary tumors included cervix (1), ovary (1), endometrial (1), prostate (1), and renal 
(1). 
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c Other included leiomyosarcoma (2), germ cell (2), mesothelioma (2), Merkel cell carcinoma 
(1), spindle cell carcinoma (1), osteosarcoma (1), adenocarcinoma of unknown primary (1), 
ciliary body melanoma (1), and ampulloma (1). 
d Included chemotherapy, hormonal therapy, immunotherapy, and targeted therapy (one 
patient with BCC was previously treated with the topical formulation of sonidegib). 
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Table 2. Most Common Adverse Events (All Grades, ≥ 5% Incidence) Suspected to Be 
Related to Sonidegib Treatment 
  Once-Daily Doses, mg Twice-Daily Doses, mg 
Total Adverse 
Events (%) 
Grade 3/4 (%)a 
100  
(n = 
6) 
200  
(n = 
6) 
400 
(n = 
5) 
800 
(n = 
26) 
1000 
(n = 
11) 
1500 
(n = 
9) 
3000 
(n = 
10) 
250  
(n = 
14) 
400  
 (n = 
8) 
750 
 (n = 
8) 
All  
(n = 
103) 
Gastrointestinal 
toxicity 
                      
     Nausea 3 1 0 4 3 4 2 3 1 5 
26 
(25.2) 
     Dysgeusia 1 1 0 5 3 3 5 6 3 3 
30 
(29.1) 
     Anorexia 
2 
 
1 
 
1 
 
8 
1 
4 
 
0 
 
4 
 
5 
 
3 
 
2 
 
30 
(29.1) 
1 (1.0) 
     Vomiting 1 1 0 3 1 1 1 2 1 2
13 
(12.6)
     Diarrhea 0 0 0 2 0 0 1 1 1 2 7 (6.8)
     Constipation 0 1 0 1 1 0 1 0 0 2 6 (5.8)
Muscle spasms 
2 2 0 9 3 4 0 5 4 4 
33 
(32.0) 
Myalgia 
0 
 
1 
 
0 
 
4 
 
3 
1 
2 
 
2 
 
3 
 
0 
 
2 
 
17 
(16.5) 
1 (1.0) 
Blood CK 
increased 
1 
 
1 
 
0 
 
7 
2 
4  
2 
3 
3 
4  
3 
3 
2 
4     
2 
6     
5 
33 
(32.0)  
19 
(18.4) 
Increased 
transaminasesb 
0 
 
0 
 
0 
 
2 
 
0 
 
2 
 
2 
2 
6 
2 
2 
1 
1 
1 
15 
(14.6) 
6 (5.8) 
Fatigue/asthenia 
5 
 
2 
 
0 
 
6 
1
4 
1
3 
1
0 
 
4 
 
3 
 
1 
 
28 
(27.2)  
3 (2.9)
Alopecia 
1 1 0 4 1 2 1 1 2 0 
13 
(12.6) 
Lethargy 0 0 0 3 1 0 1 1 0 1 7 (6.8) 
Abbreviations: ALT, alanine aminotransferase; AST, aspartate aminotransferase; CK, creatine 
kinase. 
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a Italicized numbers indicate grade 3/4 adverse events. 
b Includes increased AST or ALT.
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Table 3. Summary of Sonidegib PK Parameters After a Single Dose on Day 1 of PK Run-in 
and Repeated Doses on Day 15 of Cycle 1  
PK Run-in 
Dose, mg N Cmax, ng/mL Mean (SD; CV%) 
AUC0-168h‚ ng × h/mL 
Mean (SD; CV%) 
Tmax, ha
Median (min–
max) 
100 once daily 6 85.8 (52.3; 61) 1880 (1150; 61) 2 (1–24)
200 once daily 6 160 (115; 72) 3670 (2130; 58) 2 (2–48)
400 once daily 5 267 (239; 90) 7450 (8530; 115) 4 (4–4)
800 once dailyb 25 430 (381; 89) 7870 (6950; 88) 4 (1–27)
1000 once daily 11 322 (258; 80) 7400 (6340; 86) 2 (1–4)
1500 once daily 9 376 (199; 53) 12,600 (7110; 56) 4 (2–24)
3000 once daily 10 429 (237, 55) 11,800 (11,200; 95) 2 (1–8)
250 twice dailyb 14 150 (111; 74) 3, 20 (2320; 72) 2 (1–4)
400 twice daily 8 334 (300; 90) 7530 (7020; 93) 4 (2–4)
750 twice daily 8 226 (180; 80) 6920 (7110; 103) 3 (1–23)
Day 15, cycle 1 
Dose, mg nc Cmax, ng/mL Mean (SD; CV%) 
AUC0-24h, ng × h/mLc 
Mean (SD; CV%) 
Tmax, ha
Median (min–
max) 
100 once daily 3 155 (63.4; 41) 2690 (1340; 50) 4 (2–6)
200 once daily 5 269 (163; 61) 5920 (3890; 66) 4 (0-6)
400 once daily 4 558 (286; 51) 10,200 (5880; 58) 13 (1–24)
800 once dailyb 20 840 (457; 54) 12,800 (6350; 50) 2 (1–6)
1000 once daily 8 1230 (1400; 113) 15,200 (18,500; 122) 4 (2–6)
1500 once daily 8 1320 (657; 50) 27,400 (14,300; 52) 5 (2–24)
3000 once daily 6 1670 (1050, 62) 24,600 (8770; 36) 3 (0–21)
250 twice dailyb 13 807 (353; 44) 14,500 (4780; 33) 2 (0–6)
400 twice daily 7 864 (333; 39) 13,800 (6390; 46) 2 (0–8)
750 twice daily 8 1570 (1020; 65) 26,900 (17,300; 64) 4 (0–8)
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Abbreviations: AUC0-168h, area under the plasma concentration-time curve from time zero to 
168 hours; AUC0-24h, area under the plasma concentration-time curve from time zero to 24 
hours; Cmax, maximum plasma drug concentration; CV, coefficient of variation; PK, 
pharmacokinetic; SD, standard deviation; Tmax, time to reach Cmax. AUC0-24h for twice-daily 
doses are calculated as 2*AUC0-12h.  
a Values are median (range) and arithmetic mean (SD; CV%) for all other parameters. 
b Bold values represent maximum tolerated dose for once-daily and twice-daily doses. 
c AUC analysis on cycle 1, day 15 included 3, 3, 4, 16, 6, 3, 4, 12, 5, and 6 patients from the 
100, 200, 400, 800, 1000, 1500, 3000 mg once-daily and 250, 400, and 750 mg twice-daily 
dose cohorts, respectively.
Research. 
on February 17, 2014. © 2014 American Association for Cancerclincancerres.aacrjournals.org Downloaded from 
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. 
Author Manuscript Published OnlineFirst on February 12, 2014; DOI: 10.1158/1078-0432.CCR-13-1710 
33 
 
FIGURE LEGENDS 
Fig. 1. Relationship between sonidegib exposure and creatine kinase (CK) elevation. 
Sonidegib area under the plasma concentration-time curve from time zero to 24 hours (AUC0-
24) on day 15 of cycle 1 was plotted for each patient by dose cohort. Incidences of CK elevation 
were noted for each patient. Incidence of grade 3/4 CK elevation was associated with 
increased sonidegib exposure. Grey-filled diamonds indicate patients without grade 3 or 4 CK 
elevation; black-filled circles indicate patients who experienced grade 3 or 4 CK elevation. 
Black solid line indicates mean AUC.  
Fig. 2. Glioma-associated oncogene homolog 1 (GLI1) fold change and percent inhibition in 
normal skin by dose cohort after sonidegib treatment. GLI1 expression was analyzed in patient 
skin specimens before and after treatment with sonidegib. Fold change from baseline was 
determined and plotted by dose cohort. Sonidegib treatment induced a dose-dependent 
decrease in GLI1 expression. Dotted lines represent 50%, 60%, and 90% mean inhibition.  
Fig. 3. Responses in patients with basal cell carcinoma (BCC) treated with sonidegib. (A) 
Immunohistochemistry (IHC) of a 76-year-old male patient with BCC treated with 400 mg twice 
daily. Histologically confirmed complete response was noted after 4 months of treatment. 
Photographs (B) and IHC (C) of BCCs in a 55-year-old male patient with Gorlin syndrome 
treated with 800 mg once daily. Partial response was observed after ≈ 6 months. Circles in (A) 
highlight the presence or absence of tumor tissue; arrows in (A) highlight fibrosis.  
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